(Total Views: 88)
Posted On: 05/24/2018 10:28:31 AM
Post# of 4488
$LILY:CSE $MPHMF: Callitas Health Enters into Exclusive Development and Intellectual Property Agreement for CannaMint Strips and Files Additional Trademarks for CannaStrips and CanRelief
CINCINNATI, OH, May 24, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced today that it has signed an Exclusive Development and Intellectual Property Agreement for its patent-pending CannaMint Strips. The Company has contracted with a confidential OTC pharmaceutical development and custom packaging company to help develop, contract manufacture and package the Company’s CannaMint Strips for worldwide distribution. The confidential OTC pharmaceutical company already has patented and patent-pending substrate technology for extended release oral films that will further enhance the Callitas patent-pending delivery.
The proprietary, patent and trademark-pending CannaMint strips for THC (Tetrahydrocannabinol) and CBD (Cannabidiol) provide a unique opportunity for Callitas to position itself in the cannabinoids market. “Our patented and patent-pending technologies have the potential to be game-changers as delivery mechanisms for CBD and THC,” said James Thompson, Callitas’ Interim President and CEO.
In addition to the signed agreement, the Company has filed additional trademarks for CannaStrips and CanRelief. “Trademark protection for our additional cannabis-related products not only protects our technology, but our shareholder’s investment and long-term value as well,” Mr. Thompson said.
“These developments, combined with the addition of Dr. Gregory Smith, MD, MPH as Chief Medical Cannabis Advisor, make us a competitor in the dynamic and ever-changing THC/CBD [cannabinoids] market,” said Mr. Thompson. “These next steps are integral in increasing our visibility, viability and longevity in the industry.”
CINCINNATI, OH, May 24, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced today that it has signed an Exclusive Development and Intellectual Property Agreement for its patent-pending CannaMint Strips. The Company has contracted with a confidential OTC pharmaceutical development and custom packaging company to help develop, contract manufacture and package the Company’s CannaMint Strips for worldwide distribution. The confidential OTC pharmaceutical company already has patented and patent-pending substrate technology for extended release oral films that will further enhance the Callitas patent-pending delivery.
The proprietary, patent and trademark-pending CannaMint strips for THC (Tetrahydrocannabinol) and CBD (Cannabidiol) provide a unique opportunity for Callitas to position itself in the cannabinoids market. “Our patented and patent-pending technologies have the potential to be game-changers as delivery mechanisms for CBD and THC,” said James Thompson, Callitas’ Interim President and CEO.
In addition to the signed agreement, the Company has filed additional trademarks for CannaStrips and CanRelief. “Trademark protection for our additional cannabis-related products not only protects our technology, but our shareholder’s investment and long-term value as well,” Mr. Thompson said.
“These developments, combined with the addition of Dr. Gregory Smith, MD, MPH as Chief Medical Cannabis Advisor, make us a competitor in the dynamic and ever-changing THC/CBD [cannabinoids] market,” said Mr. Thompson. “These next steps are integral in increasing our visibility, viability and longevity in the industry.”
(0)
(0)Scroll down for more posts ▼
